ISRCTN15768185已完成不适用
ode Biopsy using Magnetic Nanoparticles: A prospective multicentre feasibility non-randomised clinical trial for melanoma
King's College London (UK)0 个研究点目标入组 160 人开始时间: 2013年8月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with primary cutaneous melanoma scheduled for SLNB and who are clinically AJCC stage IB-IIC.
- •2. Patients available for follow-up for at least 12 months
- •Lower Age Limit 18 years
排除标准
- •1. Intolerance / hypersensitivity to iron or dextran compounds
- •2. Patients who cannot / do not receive radioisotope for SLNB
- •3. Patients with pacemakers or other implantable devices in the chest wall
- •4. Patients who had previous surgery to the likely draining lymph node fields
- •5. Patients with surgical scars between the primary biopsy site the draining lymph node field that may alter the lymphatic drainage pattern
- •6. Patients with pre-existing lymphedema at the primary biopsy site, either primary or secondary
研究者
相似试验
已完成
2 期
Sentinel Node Biopsy using Magnetic Nanoparticles: A prospective multicentre phase II non-randomised clinical trial to compare sentinel node biopsy using magnetic nanoparticles vs. standard techniqueNL-OMON40081King's College London75
招募中
不适用
SentiMag Multicentre Trial.Breast CancerSentinel Lymph Node Biopsy (SLNB)Detection of Lymph Node metastases using MRINL-OMON23320This trial is jointly sponsored by King’s College London and Guy’s & St Thomas’ NHS Trust. The trial is being coordinated by the SentiMAG Trials Office, Department of Research Oncology, King’s College London.160
已完成
不适用
SentiMAG multicentre trialMalignant neoplasm of breastBreast CancerCancerISRCTN35827879King's College London (UK)160
尚未招募
4 期
Study to evaluate iron oxide nanoparticles as suitable medicament in children teethCTRI/2022/02/040656Dr Charul Kumari
已完成
不适用
tilizing magnetic nanoparticles in prostate cancer for sentinel and aberrant lymph node mappinglymph node metastases10027656Prostate cancerNL-OMON50068niversitieit Twente20